0001213900-24-030958.txt : 20240405
0001213900-24-030958.hdr.sgml : 20240405
20240405214530
ACCESSION NUMBER: 0001213900-24-030958
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240405
DATE AS OF CHANGE: 20240405
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dumesnil Simon
CENTRAL INDEX KEY: 0001875691
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40804
FILM NUMBER: 24827970
MAIL ADDRESS:
STREET 1: 1111 LINCOLN ROAD
STREET 2: SUITE 500
CITY: MIAMI BEACH
STATE: FL
ZIP: 33139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Pasithea Therapeutics Corp.
CENTRAL INDEX KEY: 0001841330
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 851591963
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2110 NARCISSUS CT
CITY: VENICE
STATE: CA
ZIP: 90291
BUSINESS PHONE: 8184226172
MAIL ADDRESS:
STREET 1: 2110 NARCISSUS CT
CITY: VENICE
STATE: CA
ZIP: 90291
4/A
1
ownership.xml
X0508
4/A
2024-03-01
2024-03-01
0
0001841330
Pasithea Therapeutics Corp.
KTTA
0001875691
Dumesnil Simon
1111 LINCOLN ROAD,
SUITE 500
MIAMI BEACH
FL
33139
1
0
0
0
0
Stock Option (right to buy)
8.13
2024-03-01
4
A
0
7500
0
A
2034-02-28
Common Stock
7500
7500
D
The sole purpose of this Form 4/A is to correct the exercise price, which was previously reported erroneously as $8.34 per share. The correct exercise price, based upon the closing price of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on March 1, 2024, was $8.13 per share.
The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan. The shares of Common Stock underlying the Option will vest at the rate of 33% upon the one-year anniversary of the date of grant and 33% on each successive one-year anniversary thereafter; provided, that the Reporting Person remains a director of the Issuer through such vesting date.
On January 2, 2024, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Common Stock, and the exercise price and shares of Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person.
/s/ Simon Dumesnil
2024-04-05